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1. Introduction  
Lymphoproliferative disorders (LPDs) represent a heterogeneous group of expanding, 
monoclonal or oligoclonal, lymphoid cells that occur in the setting of immune dysfunction. 
They are sometimes equated with "immunoproliferative disorders", but technically LPDs are 
a subset of immunoproliferative disorders, along with hypergammaglobulinemia and 
paraproteinemias. Several inherited gene mutations have been identified to cause 
lymphoproliferative disorders. Acquired and iatrogenic causes are also responsible for the 
appearance of these diseases. 
The most common examples of LPDs are chronic lymphocytic leukemia, acute 
lymphoblastic leukemia, lymphomas/leukemias (including follicular lymphoma and hairy 
cell leukemia) and multiple myeloma, although less common LPDs such as post-transplant 
lymphoproliferative disorder, Waldenström's macroglobulinemia, Wiskott-Aldrich 
syndrome and Autoimmune LymphoProliferative Syndrome (ALPS) also belong to the 
same group of disorders. 
A few basic current facts for the incidence rates, the prognosis and the treatment of the most 
common LPDs will be briefly mentioned in the beginning of this chapter. Following that, the 
recent advances in understanding the pathogenesis of these diseases coming from 
experimental animal studies will be reviewed in a greater detail. After all, understanding 
the mechanisms of neoplasia has always been a prerequisite for developing more effective 
treatments for cancer patients, and the sophisticated animal models available in our days 
have played a major role in enhancing this knowledge. We have developed an animal model 
for Waldenström's macroglobulinemia (WM), which is one of the less common LPDs. This 
will also be presented in detail as an example of the challenges met in developing an animal 
model that should emulate the human disease, or at least important aspects of it. By 
introducing core biopsies of WM patients into immunodeficient mice bearing human bone 
fragments, we established an animal model mimicking important aspects of the disease in 
humans.  
www.intechopen.com
 Hematology – Science and Practice 
 
426 
2. Lymphoproliferative disorders 
2.1 Chronic lymphocytic leukemia  
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America 
and Europe; it is less frequent in Asia and Africa (Linet et al., 2006). The reported age-
adjusted incidence rate of CLL in the United States between 1975 and 2006 was 4.43 per 
100,000 persons (Horner et al., 2009). However, because of its long asymptomatic period, the 
incidence of CLL is under-reported in cancer registries (Dores et al., 2007). 
Despite this uncertainty, it is clear that the incidence of CLL rises dramatically with age and 
that it is more common in men than women (Dores et al., 2007; Redaelli et al., 2004). As the 
proportion of older people has increased with improved life expectancy in the Western 
world, the CLL burden has also increased. The American Cancer Society projected 15,490 
new cases for 2009, a substantial increase from the 11,168 new cases reported in 2005 (U.S. 
Cancer Statistics Working group, 2009). The disease burden is also significant in the 
European Union, with an estimated 46,000 individuals in 2006 living with CLL 5 years post-
diagnosis (Watson et al., 2008). 
CLL is characterized by a variable clinical course (Rozman & Montserrat, 1995) with some 
patients having an aggressive malignancy and others a slow, nonprogressive disease and a 
virtually normal life expectancy. Ideally, a detailed diagnostic workup of a CLL case should 
include the identification of standardized and reliable prognostic factors. Predicting the 
outcome of CLL with a statistically significant level of success will provide the basis for 
individualized therapeutic approaches and patient-adjusted disease management policies. 
Indeed, several prognostic factors, including serum (Hallek et al., 1999) and cytogenetic 
alteration markers (Dohner et al., 2000), have been used to assist individual CLL patient 
prognosis. 
2.2 Acute lymphoblastic leukemia 
There are two types of acute leukemia: acute myelogenous leukemia (AML) and acute 
lymphoblastic leukemia (ALL); (Ashfaq et al., 2010). Acute myelogenous leukemia (AML) is 
a clonal, malignant disease of hematopoietic tissue that is characterized by the proliferation 
of abnormal (leukemic) blast cells, principally in the marrow, and by impaired production of 
normal blood cells (Lichtman & Liesveld, 2001). It is the most common acute leukemia 
affecting adults, and its incidence increases with age. AML accounts for nearly one-third of 
all new cases of leukemia (Ashfaq et al., 2010). 
Acute lymphoblastic leukemia is a neoplastic disease that results from somatic mutation in a 
single lymphoid progenitor cell at one of several discrete stages of development. The 
immunophenotype of the leukemic cells at diagnosis reflects the level of differentiation 
achieved by the dominant clone (Pui, 2001). At diagnosis the leukemic cells not only have 
replaced normal marrow cells but have disseminated to various extramedullary sites. 
Studies suggest that the activation of telomerase in leukemic cells contribute to their growth 
advantage and to disease progression (Ohyashiki et al., 1997; Shay et al., 1996). 
ALL represents about 12 percent of all leukemias diagnosed in the US, and 60 percent of all 
cases occur in persons younger than 20 years (SEER, 1998). ALL is the most common 
malignancy diagnosed in patients under the age of 15 years, accounting for one-fourth of all 
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cancers and 76 percent of all leukemias in this age group (Gurney et al., 1996). Data from UK 
showed that there were 691 new cases of ALL and 255 deaths from ALL in 2006 (Cancer 
Research U.K., 2010). Each year, around 3,250 children are diagnosed with leukemia, of 
which about 2,400 are ALL cases (Smith et al., 2000). In the USA, survival rate for children 
with ALL has improved markedly since the early 1970s and is now approximately 80%, but 
incidence rates have not decreased and have, in fact, increased by 0.8% annually from 1975 
to 2007 (SEER, 2010). Worldwide, according to the World Health Organization (WHO), there 
were 33,142 deaths from leukemia among children under age 15 in 2004, and childhood (<15 
years) leukemia caused 1,228,075 disability adjusted life years (WHO, 2010).  
Identifying risk factors for childhood leukemia is an important step in the reduction of the 
overall burden of childhood diseases. Though it has been studied intensively, the etiology of 
childhood leukemia is not well established. A two-hit model was proposed by Greaves in 
which prenatal chromosome alterations and postnatal genetic alterations are necessary for 
childhood leukemia development (Greaves, 2002). Genetic susceptibility and environmental 
factors play potential roles in this process (Eden, 2010). Ionizing radiation has been 
significantly linked to childhood leukemia (Bailey et al., 2010). Evidence for an association 
with benzene exposure or with parental smoking and alcohol consumption is less 
convincing (Liu et al., 2011) . 
Treatment for the majority of ALL subtypes consists of three phases: induction, 
intensification (consolidation) therapy, and continuation (maintenance) treatment. Although 
two-thirds of childhood cases are curable with only 12 months of treatment, the vast 
majority of patients undergo therapy for two years or more (Pui & Evans, 2006). Across 
medical institutions, chemotherapeutic agents used vary in type and amount, with the most 
common being methotrexate (MTX), cytosine arabinoside (cytarabine), anthracyclines (such 
as doxorubicin), asparaginase, mercaptopurine, vincristine, and corticosteroids, presented 
alone or in combination (Pui & Evans, 2006). Leukemic cells are transported by the 
circulatory system to nearly every organ system, including the Central Nervous System 
(CNS). The most common form of CNS prophylaxis was cranial irradiation, or cranial 
radiation therapy (CRT), which has largely been replaced by intrathecal (IT) and systemic 
chemotherapy. This change has been made in an effort to eliminate radiation-specific 
damage to the CNS (Stehbens et al., 1991). Recent regimens have tested whether CRT can be 
eliminated completely from standard treatment. To date, this has been successful, although 
alterations in long-term outcome are just beginning to unfold (Pui et al., 2009). Efforts like 
this are being made to eliminate the possible complications of any form of ALL treatment. 
2.3 Lymphomas/leukemias  
Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a 
leading cause of cancer-related mortality. Recent cancer statistics for the United States 
project non-Hodgkin lymphoma (NHL) to be the sixth most commonly diagnosed cancer in 
2010 in both men and women, and the eighth and sixth leading cause of cancer-related 
death in men and women, respectively (Jemal et al., 2010). Based on data from national 
cancer registries, 65,540 new cases of NHL and 20,210 deaths from NHL are estimated to 
occur in 2010. In contrast, Hodgkin lymphoma (HL) is less common (8,490 estimated new 
cases in 2010) and is associated with fewer deaths (1,320 estimated deaths in 2010) (Jemal et 
al., 2010). In the European Union, reported NHL estimates for the year 2006 were even 
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higher, with 72,800 new cases and 33,000 deaths (Ferlay et al., 2007). In the US, on January 1, 
2008, there were approximately 167,000 HL survivors and approximately 454,000 NHL 
survivors (Howlader et al., 2011). In the Nordic European Countries (NEC: Denmark, Faroe 
Islands, Finland, Iceland, Norway, Sweden), there were approximately 10,500 HL survivors 
and approximately 31,500 NHL survivors at the end of 2007 (Engholm et al., 2011). 
Although there are similarities between these subtypes of lymphoma, the incidence and age 
of onset are quite different.  
Onset of the disease occurs most frequently between the ages of 20 and 35 years. Between 35 
and 50 years, it occurs less often especially in females, but from the age of 50 onward there is 
again a rise in incidence with age (Howlader et al., 2011). The disease occurs predominantly 
in individuals aged over 45 years and the lifetime prevalence of NHL is one in 50 (Howlader 
et al., 2011). Due to chemotherapy, radiotherapy and stem cell transplantation, the survival 
of these patients has improved substantially in the seventies and eighties, but has nowadays 
leveled off. In effect, most trials focus on maintaining the high level of cure, while reducing 
the long-term effects of treatment. To date, more than 80% of patients diagnosed with HL 
are expected to live free of disease for 5 years or more after diagnosis (National Cancer 
Institute, 2009) The overall 5-year survival rate for all types of NHL (1999–2005) is 50–60%. 
The statistics vary depending on the cell type, stage of disease at diagnosis, treatment and 
age of the patient (National Cancer Institute, 2009). 
Indolent Non-Hodgkin's lymphoma (NHL) represents a group of incurable slow growing 
lymphomas that are highly responsive to initial therapy but relapse with less responsive 
disease (Ardeshna et al., 2003; Horning, 1993; Johnson et al., 1995; Montoto et al., 2002). The 
landscape for treatment of indolent NHL has dramatically changed with the introduction of 
rituximab (Rituxan, Genetech, San Francisco, CA). Its greatest impact has been in follicular 
lymphoma (FL), which constitutes approximately 70% of indolent lymphomas and up to 
25% of all cases of NHL (Marcus et al., 2005; The Non-Hodgkin's Lymphoma Classification 
Project, 1997). Although there are no defined first line therapies for indolent NHL, rituximab 
has become a standard component in treatment of Follicular Lymphoma (FL) (Friedberg et 
al., 2009). While indolent lymphoma remains an incurable disease, recent data from the 
Surveillance Epidemiology and End Results (SEER) database and retrospective analysis of 
clinical trials in indolent NHL suggest an improved overall survival with the use of 
rituximab (Fisher et al., 2005; Liu et al., 2006; Pulte et al., 2008). It is hoped that overall 
survival can be further improved with the use of extended rituximab dosing schedules. 
2.4. Multiple Myeloma  
Multiple Myeloma (MM) is a B cell malignancy characterized by the presence of bone 
marrow infiltration by clonal plasma cells that generally secrete a monoclonal component in 
the serum or urine (Kyle & Rajkumar, 2004). It is the second most frequent hematological 
malignancy, after non Hodgkin’s lymphomas, and accounts approximately for a 10% of all 
hematological tumors and 1% of all cancers (Petrelli et al., 2009). MM is associated with a 
constellation of disease manifestations, including osteolytic lesions due to disrupted bone 
metabolism, anemia and immunosuppression due to loss of normal hematopoietic stem cell 
function, and end-organ damage due to monoclonal immunoglobulin secretion (Barlogie et 
al., 2001). The presence of somatic hypermutations of the immunoglobulin variable region 
genes in myeloma plasma cells suggests that malignant transformation occurs in a B cell that 
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has traversed the germinal centers of lymph nodes. However, the hypoproliferative nature 
of myeloma has led to the hypothesis that the bulk of the tumor arises from a transformed B 
cell with the capacity for both self-renewal and production of terminally differentiated 
progeny (Billadeau et al., 1993; Corradini et al., 1993; Szczepek et al., 1998). 
The clinical course of patients requiring therapy for myeloma varies markedly. Even with 
tandem autotransplants yielding complete remission (CR) rates in excess of 60%. Survival 
ranges from a few months to greater than 15 years. The extended time (almost 2 years) for 
those patients to achieve CR, and the even longer time to achieve magnetic resonance 
imaging (MRI)–CR, strongly suggests enormous tumor cell population heterogeneity in 
terms of drug responsiveness/resistance (Harousseau et al., 2004). 
Differential expression of traditional prognostic factors, such as 2-microglobulin (2M), 
albumin, and C-reactive protein (CRP), are thought to be responsible for only a 15%–20% of 
the outcome heterogeneity of MM. Abnormal metaphase karyotypes, present in one-third of 
newly diagnosed patients and reflecting stroma independence, have been consistently 
associated with a rapidly fatal outcome, and fewer than 10% of patients with these 
abnormalities survive > 5 years (Harousseau et al., 2004). 
Advances in molecular cytogenetics have identified primary translocations involving the 
immunoglobulin heavy chain locus at 14q32 in 40% of patients (Kuehl & Bergsagel; 2002). 
According to a consensus report of a Paris workshop on myeloma genetics, hyperdiploid 
and t(11;14)(q13,q32)-positive myeloma are associated with a good prognosis, whereas non-
hyperdiploidy, often associated with translocations other than t(11;14) and chromosome 13 
deletion, imparts a strikingly dismal prognosis (Fonseca et al., 2004). 
2.5 Other lymphoproliferative disorders 
Along with Waldenström's macroglobulinemia, there are other LPDs, which are less 
frequently observed. From this group we will describe in more details the 
lymphoproliferative disorders detected after bone marrow and organ transplantation. 
Following this treatment and among patients infected with AIDS, LPDs are believed to 
result from uncontrolled proliferation of Epstein-Barr virus (EBV)-transformed B-
lymphocytes in the setting of immune dysfunction (Cohen, 1991; Deeg & Socié, 1998; 
Goedert et al., 1998; Hoover, 1992; Kinlen, 1996; Newell et al., 1996; Opelz & Henderson, 
1993; Swinnen et al., 1990). Allogeneic bone marrow transplantation, an effective treatment 
for leukemia and other disorders, produces profound immune deficiency in the early period 
after transplantation. Post-transplant lymphoproliferative disorders (PTLD) are an 
uncommon, but frequently fatal, complication of this defective immune function (Bhatia et 
al., 1996; Deeg & Socié, 1998; Witherspoon et al., 1989). PTLD typically develop in the first 6 
months post-transplantantation as clinically aggressive lymphomas of donor origin; most 
are related to EBV (Deeg & Socié, 1998; Orazi et al., 1997; O’Reilly et al., 1996). 
Post-transplant lymphoproliferative disorders are more common if donor and recipient are 
HLA-mismatched or if T-cell depletion is used for graft-versus-host disease (GVHD) 
prophylaxis (Curtis et al., 1999). The clinical diagnosis of PTLD may be difficult because it is 
a spectrum of heterogenous histologic and clinical entities. It may present as an infectious 
mononucleosis-like illness, with fatigue and lymphadenopathy, or as a febrile illness with 
leukopenia. Almost all organs may be affected by disease. Because of the progressive nature 
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of PTLD, the key to management may be early or even preemptive treatment with either 
anti–B-cell monoclonal antibodies (Carpenter et al., 2002; Kuehnle et al., 2000; van Esser et 
al., 2002) or donor-derived EBV-specific cytotoxic T lymphocytes (CTLs) (Gustafsson et al., 
2000; Heslop et al., 1996; Rooney et al., 1998).  
3. Animal models of lymphoproliferative disorders  
The bulk of LPD-related literature describes the different clinical manifestations 
encountered and evaluates treatment protocols. Fewer studies focus on dissecting the 
pathogenesis of LPD by developing animal models. Recent basic research is based on the 
development of genetically engineered mice or the use of immunodeficient mice as tumor 
transplant models. A few animal models other than mice have also been reported (miniature 
swine, zebrafish). 
3.1 Chronic lymphocytic leukemia  
Chronic lymphocytic leukemia cells require complex microenvironmental and immunologic 
interactions to survive and proliferate. Such interactions might be best studied in animal 
models; however, this needs extensive verification. Hofbauer et al. (2011) therefore 
investigated the composition of the T-cell compartment in the ETCL1 transgenic mouse, 
currently the most widely used murine model for CLL. TCL1 is a bona fide oncogene, 
developing a transgenic mouse model where ectopic expression driven by the lck promoter 
in the T cell compartment results in the development of mature T cell leukemias after a long 
latency period, in a pattern closely resembling human mature T cell leukemia (Virgilio et al., 
1998). Immunophenotyping and transplant approaches were used to define T-cell subsets at 
various stages of CLL. Analogous to human CLL, they observed a skewing of T-cell subsets 
from naive to antigen-experienced memory T cells that was more pronounced in lymph 
nodes than in blood. Transplantation of CLL into non-transgenic recipients was feasible 
without immunosuppression in a pure C57BL/6 background and resulted in the prominent 
skewing of the T cells of the recipient mice. Both in spontaneously developed CLL and in 
the transplantation setting, a loss in T-cell receptor diversity was observed, with a relevant 
number of clonal T-cell populations arising. This suggests that antigen-dependent 
differentiation toward the T memory pool is initiated by murine CLL cells. In summary, this 
research team characterized the T-cell phenotypes in the TCL1 transgenic mouse model and 
suggested a CLL-dependent antigen-driven skewing of T cells in these mice, making this 
model valuable for the research of the disease’s pathogenesis, since murine CLL cells react 
similarly with human CLL cells.  
The same transgenic mouse (ETCL1 transgenic mouse,) was also used by Suljagic et al. 
(2010). They have investigated whether inhibition of BCR (antigen-dependent B-cell 
receptor) signaling with the selective Syk inhibitor fostamatinib disodium (R788) had an 
affect on the growth of the leukemias that develop in the ETCL1 transgenic mouse model 
of CLL. Similarly to human CLL, these leukemias express stereotyped BCRs that react with 
autoantigens exposed on the surface of senescent or apoptotic cells, suggesting that they are 
antigen driven. They showed that R788 effectively inhibits BCR signaling in vivo, resulting 
in reduced proliferation and survival of the malignant B cells and significantly prolonged 
survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the 
relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, 
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suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. 
Importantly, the effect of R788 was found to be selective for the malignant clones, as no 
disturbance in the production of normal B lymphocytes was observed. Collectively, these 
data provide further rationale for clinical trials with R788 in CLL and establish the BCR-
signaling pathway as an important therapeutic target in this disease. 
In another approach, over-expression of human TCL1, leads to the development of mature 
CD19+/CD5+/IgM+ clonal leukemia with a murine disease phenotype similar to the human 
CLL. Herein, Chen et al. (2009) review their recent study using this TCL1-driven mouse model 
for CLL and corresponding human CLL samples in a cross-species epigenomics approach to 
address the timing and relevance of epigenetic events occurring during leukemogenesis. They 
demonstrated that the mouse model recapitulates the epigenetic events that have been 
reported for human CLL, affirming the power and validity of this mouse model to study early 
epigenetic events in cancer progression. Epigenetic alterations are detected as early as three 
months after birth, far before disease manifests at about 11 months of age. These mice undergo 
NFǋ-B repressor complex-mediated inactivation of the transcription factor Foxd3, whose 
targets become aberrantly methylated and silenced in both mouse and human CLL. Overall, 
their data suggest the accumulated epigenetic alterations during CLL pathogenesis as a 
consequence of gene silencing through TCL1 and NFǋ-B repressor complex, suggesting the 
relevance for NFǋ-B as a therapeutic target in CLL. 
Another trangenic mouse model for CLL was generated by Santanam et al. (2010). They found 
that miR-29a is up-regulated in indolent human B-CLL as compared with aggressive B-CLL 
and normal CD19(+) B cells. To study the role of miR-29 in B-CLL, they generated E-miR-29 
transgenic mice overexpressing miR-29 in mouse B cells. Flow cytometric analysis revealed a 
markedly expanded CD5(+) population in the spleen of these mice starting at 2 months of age, 
with 85% (34/40) of miR-29 transgenic mice exhibiting expanded CD5(+) B-cell populations, a 
characteristic of B-CLL. On average, 50% of B cells in these transgenic mice were CD5 positive. 
At 2 years of age the mice showed significantly enlarged spleens and an increase in the CD5(+) 
B-cell population to approximately 100%. Of 20 E-miR-29 transgenic mice followed to 24-26 
mo of age, 4 (20%) developed frank leukemia and died of the disease. These results suggest 
that the dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL, giving 
another opportunity to clarify all of its aspects. 
The engraftment of cell lines into appropriate mice and/or the injection of fresh cells 
derived from patients have been used for the development of animal models in different 
disesases. Here, we describe one animal model where the researchers have developed a 
novel transplantable xenograft murine model of CLL by engrafting the CLL cell line MEC1 
into Rag2(-/-)gamma(c)(-/-)mice. These mice lack B, T, and natural killer (NK) cells, and, in 
contrast to nude mice that retain NK cells, appear to be optimal recipient for MEC1 cells, 
which were successfully transplanted through either subcutaneous or intravenous routes. 
The result is a novel in vivo model that has systemic involvement, develops very rapidly, 
allows the measurement of tumor burden, and has 100% engraftment efficiency. This model 
closely resembles aggressive human CLL and could be very useful for evaluating both the 
biologic basis of CLL growth and dissemination as well as the efficacy of new therapeutic 
agents (Bertilaccio  et al., 2010).  
Another model has been developed by Aydin et al. (2011), and is exploring the role of CD38 
and functionally associated molecular risk factors in a recently described CLL nonobese 
www.intechopen.com
 Hematology – Science and Practice 
 
432 
diabetic/severe combined immunodeficient xenograft model. Intravenous injection of 
peripheral blood mononuclear cells from 73 patients with CLL into 244 mice resulted in 
robust engraftment of leukemic cells into the murine spleens detected 4 weeks after 
transplantation. Leukemic cell engraftment correlated significantly (P < 0.05) with markers 
reflecting disease activity, e.g., Binet stage and lymphocyte doubling time, and the 
expression of molecular risk factors including CD38, CD49d, ZAP-70, and IgVH mutational 
status. Increased engraftment levels of CD38+ as compared to CD38- CLL cells could be 
attributed, in part, to leukemic cell proliferation as evidenced by simultaneous  
immunostaining of murine spleen sections for Ki-67 and CD20. In short-term (24 h) homing 
assays, CD38+ CLL cells migrated more efficiently to the bone marrow of the recipient 
animals than their CD38- counterparts. Finally, the expression of CD38 by the leukemic cells 
was found to be dynamic in that it was regulated not only by elements of the murine 
microenvironment but also by co-engrafting non-malignant human T cells. This model 
could be useful for evaluating the biological basis of CLL growth in the context of the 
hematopoietic microenvironment as well as for preclinical testing of novel compounds. 
Last, but not least we describe the New Zealand Black (NZB) mouse model for CLL. Is a (de 
novo) mouse model of spontaneous CLL (Phillips et al., 1992), in contrast to all other models, 
which are induced by the expression of exogenous genes (Scaglione et al., 2007). Similar to a 
subset of human patients who progress from monoclonal B lymphocytosis (MBL) to CLL, 
NZB mice develop an age-associated progression to CLL. The murine disease is linked to a 
genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-
15a/16 (Salerno et al., 2010).  
Similar to CLL, the disease in NZB mice is also an age-associated malignant expansion of 
poly-reactive CD5+ B-1 clones (Caligaris-Cappio & Ghia, 2007; Scaglione et al., 2007). The 
majority of B-1 clones are IgM+, B220 (CD45R)dim and CD5dim , increase with age, and often 
possess chromosomal abnormalities (Dang et al., 1996). NZB also seem to demonstrate an 
MBL-like stage at an early age, characterized by multiple clones, as seen in MBL cases 
reported by Lanasa et al. (2010). High levels of IL-10 are also correlated with the 
development of these malignant B-1 cells (Ramachandra et al., 1996). This MBL-like state in 
NZB precedes CLL, and although it exhibits similar manifestations to human MBL, NZB 
disease always progress to CLL, in contrast to humans who can have an indefinite state of 
indolent MBL disease (Lanasa et al., 2010). The NZB has also been studied as a model for 
autoimmunity (Theofilopoulos, 1996). Similar to the autoreactivity associated with CLL 
autoantibodies (Ghia et al., 2002), the NZB mouse develops a mild autoimmune reaction 
associated with B cell hyperactivity, resulting in autoimmune hemolytic anemia and 
antinuclear antibodies (Scaglione et al., 2007).  
The diversity of exisitng animal models of CLL leads to multiple options for treatment 
approaches, which is the end-point of this research. 
3.2 Acute lymphoblastic leukemia 
The non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mouse 
model is currently one of the most successful models for studying haematological 
malignancies such as acute lymphoblastic leukaemia (ALL) (Macor et al., 2008). In this 
typical tumor transplant model patient bone marrow leukemia cells are directly 
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transplanted into the recipient NOD/SCID mice (Lock et al., 2002). The kinetics of 
engraftment reflect the human disease, leading to bone marrow (BM) infiltration, followed 
by migration to the spleen, peripheral blood and other haematopoietic organs (Lock et al., 
2002; Kamel-Reid et al., 1989; Nijmeijer et al., 2001). However, for this model to be effective 
for studying engraftment and therapy responses at the whole genome level, careful 
molecular characterization is essential. 
In the ALL NOD/SCID xenograft model, Samuels et al. (2010) have combined all existing 
xenograft models and sought to validate species-specific gene expression. Using the human 
Affymetrix whole transcript platform they analyzed transcriptional profiles from engrafted 
tissues (e.g. bone marrow, spleen and/or peripheral blood) without prior cell separation of 
mouse cells and acquired highly reproducible profiles in xenografts from individual mice. 
The model was further tested with experimental mixtures of human and mouse cells, 
demonstrating that the presence of mouse cells does not significantly distort expression 
profiles when xenografts contain 90% or more human cells. In addition, they presented a 
novel in silico and experimental masking approach to identify probes and transcript clusters 
susceptible to cross-species hybridization. Hence, they demonstrated that species-specific 
transcriptional profiles can be obtained from xenografts when high levels of engraftment are 
achieved or with the application of transcript cluster masks. Importantly, this masking 
approach can be applied and adapted to other xenograft models where human tissue 
infiltration is lower. This model provides a powerful platform for identifying genes and 
pathways associated with ALL disease progression and response to therapy in vivo. 
A genetically defined mouse retroviral transduction/bone marrow transplantation model 
was used by Medyouf et al. (2010) to investigate the possibility for NOTCH1 to act as a 
therapeutic target. This is based on the assumption that NOTCH1 is activated by mutation 
in more than 50% of human T-cell acute lymphoblastic leukemias (T-ALLs) and inhibition of 
Notch signaling causes cell-cycle/growth arrest. The tumor suppressor phosphatase and 
tensin homolog (PTEN) is also mutated or lost in up to 20% of cases. It was recently 
observed among human T-ALL cell lines that PTEN loss correlated with resistance to Notch 
inhibition, raising concern that patients with PTEN-negative disease may fail Notch 
inhibitor therapy. They observed primary murine leukemias to remain dependent on 
NOTCH1 signaling despite Pten loss, with or without additional deletion of 
p16(Ink4a)/p19(Arf). They also examined 13 primary human T-ALL samples obtained at 
diagnosis and found no correlation between PTEN status and resistance to Notch inhibition. 
Furthermore, they noted  that Pten loss accelerated disease onset and produced multiclonal 
tumors, suggesting NOTCH1 activation and Pten loss may collaborate in leukemia 
induction. Thus, in contrast to previous findings with established cell lines, these results 
indicate that PTEN loss does not relieve primary T-ALL cells of their "addiction" to Notch 
signaling. They concluded that refractory/relapsed tumors that have undergone 
chemotherapy-induced mutation and/or selection may behave differently, but presumably 
will harbor many other genetic alterations besides PTEN loss. This conclusion, along others 
of the same research team provide new insight on the therapeutic management of ALL. 
Introduction of cells into syngeneic mice is also useful tool for the investigation of ALL and 
its therapeutic approach. Cultured p185(BCR-ABL)-expressing (p185+) Arf (-/-) pre-B cells 
injected into healthy syngeneic mice induces aggressive acute lymphoblastic leukemia 
(ALL) that genetically and phenotypically mimics the human disease (Boulos et al., 2011). 
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They adapted the Philadelphia chromosome-positive (Ph(+)) ALL animal model for in vivo 
luminescent imaging to investigate disease progression, targeted therapeutic response, and 
ALL relapse in living mice. Mice bearing high leukemic burdens (simulating human Ph(+) 
ALL at diagnosis) entered remission on maximally intensive, twice-daily dasatinib therapy, 
but invariably relapsed with disseminated and/or central nervous system disease. Their 
research concluded that although non-tumor-cell-autonomous mechanisms can prevent full 
eradication of dasatinib-refractory ALL in this clinically relevant model, the emergence of 
resistance to BCR-ABL kinase inhibitors can be effectively circumvented by the addition of 
"conventional" chemotherapeutic agents with alternate antileukemic mechanisms of action. 
Thus, preclinical trials using multiple agents underscore the potential value of this murine 
Ph+ ALL model for efficiently and cheaply piloting combination therapies and for 
elucidating mechanisms of drug resistance, information that is much more difficult to 
extract from complex human clinical trials. 
Other researchers have combined ALL models with exogenous factors, to test their influence 
in disease. For example, Yun et al. (2010) developed animal models of obesity and leukemia 
to test whether obesity could directly accelerate acute lymphoblastic leukemia (ALL) using 
BCR/ABL transgenic and AKR/J mice weaned onto a high-fat diet. Mice were observed 
until development of progressive ALL. Although obese and control BCR/ABL mice had 
similar median survival, older obese mice had accelerated ALL onset, implying a time-
dependent effect of obesity on ALL. Obese AKR mice developed ALL significantly earlier 
than controls. The effect of obesity was not explained by WBC count, thymus/spleen 
weight, or ALL phenotype. However, obese AKR mice had higher leptin, insulin, and 
interleukin-6 levels than controls, and these obesity-related hormones all have potential 
roles in leukemia pathogenesis. In conclusion, obesity directly accelerates presentation of 
ALL, likely by increasing the risk of an early event in leukemogenesis. This is the first study 
to show that obesity can directly accelerate the progression of ALL. Thus, the observed 
associations between obesity and leukemia incidence are likely to be directly related to 
biological effects of obesity. 
Smith et al. (2010) used another animal, zebrafish, where malignant cells can be transplanted 
into sibling animals without the need for immune suppression. Using cell-transplant zebrafish 
(Langenau et al., 2003) showed that self-renewing cells are abundant in T-ALL and comprise 
0.1% to 15.9% of the T-ALL mass. Large-scale single-cell transplantation experiments 
established that T-ALLs can be initiated from a single cell and that leukemias exhibit wide 
differences in tumor-initiating potential. T-ALLs can also be introduced into clonal-outcrossed 
animals, and T-ALLs arising in mixed genetic backgrounds can be transplanted into clonal 
recipients without the need for major histocompatibility complex matching. Finally, high-
throughput imaging methods are described that allow large numbers of fluorescent transgenic 
animals to be imaged simultaneously, facilitating the rapid screening of engrafted animals. 
These experiments show that large numbers of zebrafish can be experimentally assessed by 
cell transplantation and establish new high-throughput methods to functionally interrogate 
gene pathways involved in cancer self-renewal. 
3.3 Lymphomas/leukemias  
There are numerous studies utilizing mouse models to study different lymphomas/ 
leukemias. Here, only a few representative are mentioned, since the thorough report of these 
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models is beyond the scope of this chapter. As with other LPDs, the use of knock-out 
and/or transgenic mice has been substantial to study lymphomas and leukemias. 
The first animal model we describe studies the pathogenesis of multiple hematopoietic 
malignancies simultaneously. The researchers (Zhang et al., 2011) have generated inducible 
Pten/Myc double-knockout mice (Pten(-/-)/Myc(-/-)). By comparing the hematopoietic 
phenotypes of these double-knockout mice with those of Pten(-/-) mice, they found that 
both sets of animals developed myelo- and lympho-proliferative disorders. Their study 
suggests that the deregulation of phosphoinositide 3-kinase/Akt signaling in Pten(-/-) 
hematopoietic cells protects these cells from apoptotic cell death, resulting in chronic 
proliferative disorders. Since, none of the compound-mutant mice developed acute 
leukemia or lymphoma, it is concluded that Myc is absolutely required for the development 
of acute hematopoietic malignancies. 
Other researchers (Mukherjee et al., 2011) managed to develop spontaneous T- and B-cell 
lymphomas, and leukemia in mice: Homozygous deletion of ESPL1 gene that encodes 
Separase protein (Cohesin protease Separase plays a key role in faithful segregation of sister 
chromatids by cleaving the cohesin complex at the metaphase to anaphase transition) results 
in embryonic lethality in mice and Separase overexpression lead to aneuploidy and 
tumorigenesis. By examining the ESPL1 heterozygosity using a hypomorphic mouse model 
that has reduced germline Separase activity, they reported that while ESPL1 mutant (ESPL1 
(+/hyp)) mice have a normal phenotype, in the absence of p53, mice develop spontaneous 
T- and B-cell lymphomas, and leukemia with a significantly shortened latency as compared 
to p53 null mice. Their results indicate that reduced levels of Separase act synergistically 
with loss of p53 in the initiation and progression of B- and T- cell lymphomas, which is 
aided by increased chromosomal missegregation and accumulation of genomic instability. 
ESPL1(+/hyp), p53(-/-) mice provide a new animal model for mechanistic study of 
aggressive lymphoma and also for preclinical evaluation of new agents for its therapy. 
An interesting murine model of diffuse large B-cell lymphoma (DLBCL) described by Yu et 
al. (2011), uses human DLBCL cell line LY8, to investigate its characteristics of growth  
pathogenesis and the effect of treatment protocols. LY8 cells were injected subcutaneously 
into the right flank of nude mice. Harvested tumor tissues were cut into small pieces of 1.5 
mm × 1.5 mm × 1.5 mm and implanted subcutaneously into nude mice. Tumor growth was 
monitored and the histologic characteristics were documented. Expression of LCA, CD20, 
CD79α, Ki-67, CD3, CD45RO, bcl-6, MUM-1, CD10 and bcl-2 were examined by using 
immunohistochemistry. IgH clonal rearrangement and status of three microsatellite loci 
(D14S68, D18S69, D20S199) in the xenografted tumor samples and the parental cell line LY8 
were detected using PCR amplification followed by PAGE. The subcutaneous xenograft 
DLBCL model was successfully established by using cell line LY8, and a stable growth was 
achieved up to the 9th generation. The tumor in each generation showed similar growth 
characteristics and the rate of subcutaneous tumor formation was 91.9% (114/124). The 
tumor growth was observed from the 2nd week after morphological characteristics with 
those of human DLBCL, and expressed LCA, CD20, CD79α, bcl-6, MUM-1, CD10 and bcl-2. 
The tumor of xenograft mice and cell line LY8 showed identical IgH rearrangement and 
microsatellite length. This mouse model recapitulates many features of  human DLBCL with 
high stability and repeatability. Therefore, it provides an ideal animal model for in vivo 
studies of the biological characteristics and treatment of DLBCL. 
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Gaurnier-Hausser et al. (2011) set out to determine whether dogs with spontaneous DLBCL 
(diffuse large B-cell lymphoma) have comparative aberrant constitutive NF-ǋB activity and 
to determine the therapeutic relevance of NF-ǋB inhibition in dogs with relapsed, resistant 
DLBCL. Constitutive canonical NF-ǋB activity and increased NF-ǋB target gene expression 
were detected in primary DLBCL tissue. NF-ǋB essential modulator (NEMO)-binding 
domain (NBD) peptide inhibited this activity and induced apoptosis of primary malignant B 
cells in vitro. Intratumoral injections of NBD peptide to dogs with relapsed DLBCL inhibited 
NF-ǋB target gene expression and reduced tumor burden. This work shows that dogs with 
spontaneous DLBCL share therapeutic relevance of NF-ǋB inhibition in the treatment of 
ABC-DLBCL. These results have important translational relevance for ABC-DLBCL 
treatment in human patients, and dogs with spontaneous DLBCL may represent a clinically 
relevant, spontaneous, large animal model for human ABC-DLBCL. 
Other findings suggest that increasing levels of human-derived IgG in peripheral blood from 
hu-PBL/SCID mice could be used to monitor EBV-related human B-cell lymphoma 
development in experimental animals (Tang et al., 2011). Epstein-Barr virus (EBV) has a close 
association with various types of human lymphomas. Tang et al. (2011) aimed to evaluate the 
association between human IgG concentration and EBV-associated lymphoma development in 
huPBL/SCID mice. For that, human peripheral blood lymphocytes (hu-PBL) from EBV-
seropositive donors were inoculated intraperitoneally into SCID mouse. Twenty one out of 29 
mice developed tumors in their body. Immunohistochemical staining showed that all induced 
tumors were LCA (leukocyte common antigen) positive, B-cell markers (CD20, CD79a) 
positive, and T-cell markers (both CD3 and CD45RO) negative. The tumors were diagnosed as 
human B-cell lymphomas by these morphological and immunohistochemical features. In situ 
hybridization exhibited resultant tumor cells with EBV encoded small RNA-1 (EBER-1). 
Human-derived IgG could be found in the serum of SCID mice on the 15th day following hu-
PBL transplantation, and IgG levels increased as tumor grew in 6 hu-PBL/SCID chimeras. 
These data suggest that intraperitoneal transfer of hu-PBLs from EBV+ donors to SCID mice 
leads to high human IgG levels in mouse serum and B cell lymphomas. 
3.4 Multiple Myeloma  
Plasmacytoma or myeloma can be induced in BALB/c mice by pristane oil or can develop 
spontaneously in some mouse strains (Potter, 1982; Radl, 1981). In the former, pristane oil 
induces an oil granuloma cheracterized by a chemically-induced lymphoplasmacytic 
reaction. This progresses to an autonomously growing plasmacytoma with uncontrolled 
expression of c-MYC due to its rearrangement. Generally, these plasmacytomas secrete 
monoclonal immunoglobulin of the IgA isotype. Essential monoclonal gammopathies and a 
malignancy resembling human plasma cell myeloma may arise spontaneously in inbred 
mice (Radl et al., 1988; Radl, 1991). 
Hence, the Radl model was produced using 5T myeloma cells that arose spontaneously in 
aged, inbred C57BL/KaLwRijHsd mice and is propagated by the inoculation of these 
myeloma cells into syngeneic mice. More specifically, in order to develop a better animal 
model of human myeloma bone disease, Garrett et al. (1997), have established and 
subcloned a cell line from this murine myeloma and found that it causes osteolytic bone 
lesions in mice characteristic of human myeloma bone disease. The cell line produces 
interleukin-6, but grows independent of exogenous interleukin-6. Mice inoculated 
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intravenously with the cultured cells predictably develop an identical disease to the mice 
injected intravenously with fresh bone-marrow-derived myeloma cells, including 
monoclonal gammopathy and radiologic bone lesions. They found that some of the mice 
became hypercalcemic, and the bone lesions are characterized by increased osteoclast 
activity. They found identical results when they inoculated Nu/Bg/XID mice with cultured 
murine myeloma cells. Because they can inoculate mice with precise numbers of cells and 
predict accurately when the mice will develop bone lesions, become hypercalcemic, and die, 
they considered it as a convenient model for determining the mechanisms by which the 
myeloma cells cause osteoclast activation in this model of human myeloma bone disease 
(Garrett et al., 1997; Radl et al., 1979, 1988). 
On another approach, researchers made use of two facts:  
1. Human myeloma cell lines can survive and disseminate in mice with severe combined 
immunodeficiency (SCID; Feo-Zuppardi et al., 1992; Huang et al., 1993).  
2. Fetal bone implants (SCID-hu) can sustain survival and expansion of primary human 
myeloma cells from untreated patients with a high success rate (Yaccoby et al., 1998).  
Thus, the SCID-hu model is produced, which provides a suitable in vivo read out system to 
study human myeloma biology. Tumor self-renewal capacity can be examined in relation to 
maturation stage. The contributions of host accessory cells and cytokines to disease 
manifestation and progression can also be elucidated. It is anticipated that new treatment 
principles aiming, for example, to inactivate the marrow microenvironment (e.g. 
bisphosphonates: Aparicio et al., 1998; Shipman et al., 1997) and target neoangiogenesis (e.g. 
Thalidomide: D’ Amato et al., 1994; Singhal et al., 1999) can be evaluated. Another animal 
model uses adult human bone engraftments into SCID mice. In these mice the engrafted 
human bone is injected and subsequently populated by fresh tumor cells. In that way  a 
close resemblance to human multiple myeloma has been achieved (Sjak-Shie et al., 1999).  
Similar to the extensively tested and validated SCID-hu system, which uses a human fetal 
bone (Yaccoby et al., 1998, 2002, 2006; Yaccoby & Epstein, 1999), MM cells from the majority of 
patients grow exclusively in the implanted bone and produce typical myeloma manifestations 
including stimulation of osteoclastogenesis, suppression of osteoblastogenesis, and induction 
of severe osteolytic bone disease (Fig. 1). Ethical and scientific concerns regarding the use of 
human fetal bones in the SCID-hu model of primary human myeloma prompted the 
researchers to develop a novel system that uses rabbit bones implanted subcutaneously in 
unconditioned SCID mice. Immunohistochemical analysis of the implanted bone revealed that 
the majority of bone marrow (BM) microenvironment cells such as blood vessels, osteoclasts 
and osteoblasts were of rabbit origin. The implanted bones were directly injected with 
myeloma cells from MM patients. Successful engraftment of unseparated BM cells from 85% of 
patients and CD138-selected myeloma plasma cells from 81% of patients led to the production 
of patients’ M-protein isotypes and typical myelomamanifestations (osteolytic bone lesions 
and angiogenesis of rabbit origin; Fig. 1). Myeloma cells grew exclusively in the rabbit bone, 
but were able to metastasize into another bone at a remote site in the same mouse. Cells from 
patients with extramedullary disease also grew along the outer surface of the rabbit bones. 
This demonstrates the ability of SCID-rab model, marked by a nonmyelomatous, nonhuman, 
and nonfetal microenvironment, to support the growth of CD138-expressing myeloma cells. 
This system can now be widely used to study the biology of myeloma and its manifestations 
and to develop novel therapeutic approaches for this disease (Yata & Yaccoby, 2004). 
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Conclusively, the SCID-hu/rab xenograft model provides a system where primary human 
myeloma cells can be injected into either a fetal human bone or rabbit bone that is implanted 
subcutaneously into an immunocompromised mouse (Yaccoby et al., 1998; Yata &Yaccoby, 
2004). This model (SCID-rab) has been used since its establishment for different studies, e.g. 
the effect of anti-DKK1 therapy on bone metabolism and tumor growth in a SCID-rab system, 
since DKK1 is a key player in MM bone disease and blocking DKK1 activity in myelomatous 
bones reduces osteolytic bone resorption, increases bone formation, and helps control MM 
growth (Yaccoby et al., 2007). 
The most recent study from Fowler et al. (2009) describes a model of myeloma in which the 
host microenvironment could be modified genetically. They demonstrated 5T myeloma 
establishment in recombination activating gene 2 (RAG-2)-deficient mice, which have 
improper B- and T-cell development. Importantly, these mice can be easily bred with 
genetically modified mice to generate double knockout mice, allowing manipulation of the 
host microenvironment at a molecular level. Inoculation of 5TGM1 myeloma cells into RAG-
2−/− mice resulted in myeloma development, which was associated with tumor growth 
within bone and an osteolytic bone disease, as assessed by microcomputed tomography 
(microCT), histology and histomorphometry. Myeloma-bearing RAG-2−/− mice displayed 
many features that were similar to both human myeloma and the original Radl 5T model. To 
demonstrate the use of this model, we have examined the effect of host-derived matrix 
metalloproteinase 9 (MMP-9) in the development of myeloma in vivo. 
 
Fig. 1. Growth patterns and typical disease manifestations of myeloma cells in the SCID-rab 
model. (a, b) Myeloma cells from the majority ofpatients grew exclusively in the rabbit BM 
(medullary disease). Radiographs (a) before and (b) 12 weeks after myeloma PCs injection 
show severe resorption of the myelomatous rabbit bone. (c) Myeloma PCs taken from 
extramedullary disease grew also on the outer surface of the implanted rabbit bone. (d) 
Increased activity of mulinucleate osteoclasts was detected in myelomatous rabbit bone by 
staining sections for TRAP. (e) These osteoclasts were of rabbit origin, as revealed by their 
reactivity with anti-rabbit macrophage antibody. (f, g) Myelomatous rabbit bone sections 
immunostained with antibody to factor VIII (f) and rabbit CD141 (g) demonstrate increased 
numbers of tumor-associated microvessels of rabbit origin (From Yata & Yaccoby, 2004, 
permission pending). 
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Inoculation of 5TGM1 myeloma cells into mice that are deficient in RAG-2 and MMP-9 
resulted in a reduction in both tumor burden and osteolytic bone disease when compared 
with RAG-2-deficient wild-type myeloma-bearing mice. The establishment of myeloma in 
RAG-2−/− mice permits molecular examination of the host contribution to myeloma 
pathogenesis in vivo. 
3.5 Other lymphoproliferative disorders 
Primates and swine have been used as experimental animals to develop animal models for 
post-transplant lymphoproliferative disorder (PTLD) one of the less frequently met LPDs.  
As previously mentioned, PTLD has been shown to be associated with Epstein-Barr virus 
(EBV) infection. Although primate animal models of PTLD and the use of molecular markers 
in its diagnosis had not yet been reported, Schmidtko et al. (2002) designed a study to evaluate 
the frequency, pathology, and molecular characteristics of PTLD in cynomolgus monkey 
kidney allograft recipients. Of 160 consecutive primate renal transplants performed, 5.6% 
developed PTLD 28-103 days after transplantation. In all cases, the lymph nodes were 
involved and effaced by an atypical polymorphous lymphoid proliferation of EBER+ B cells, 
diagnostic for PTLD. Focal staining for EBNA-2 was noted in tumor cells. In 67% (six of nine) 
the PTLD infiltrates were present in extra nodal sites, notably liver (56%), lung (44%), heart 
(44%), renal allograft (44%), and native kidney (22%). The spleen was infiltrated by PTLD cells 
in all four animals that had not undergone a pre-transplant splenectomy. The PTLD 
morphology was similar in all cases and predominantly of the polymorphous type, however, 
some of these showed areas that appeared minimally polymorphous. No cases of 
monomorphic PTLD were seen. By in situ hybridization, expression of the RNA product, 
homologous for EBV-encoded RNA (EBER) was identified in the PTLD tumor cells of all cases, 
indicating latent primate EBV- related infection. This report identifies a novel animal model of 
EBV associated PTLD in the setting of kidney transplantation, with valuable implications for 
managing and understanding human PTLD and oncogenesis (Schmidtko et al., 2002). 
Barth et al. (2009) developed another non-human primate facial composite tissue 
allotransplantation model to investigate strategies to achieve prolonged graft survival and 
immunologic responses unique to these allografts. For this reason, composite facial subunits 
consisting of skin, muscle, and bone were heterotopically transplanted to mixed lymphocyte 
reaction-mismatched Cynomolgus macaques. Tacrolimus monotherapy was administered 
via continuous intravenous infusion for 28 days then tapered to daily intramuscular doses. 
They concluded that Tacrolimus monotherapy provided prolonged rejection-free survival of 
composite facial allografts in this non-human primate model but was associated with the 
development of a high frequency of donor-derived PTLD tumors. The transplantation of a 
large volume of vascularized bone marrow in composite tissue allografts may be a risk 
factor for PTLD development. 
A high incidence of a PTLD is observed in miniature swine conditioned for allogeneic 
hematopoietic cell transplantation using a protocol involving T-cell depletion and 
cyclosporine therapy. Cho et al. (2004), designed a study to assess contributing factors to 
disease development. Forty-six animals were studied including 12 (26%) that developed 
PTLD. A number of risk factors for PTLD were examined, including degree of 
immunosuppression, degree of MHC mismatch and infection by a porcine lymphotrophic 
herpesvirus (PLHV-1). Flow cytometry was used to measure host and donor T- and B-cell 
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levels in the peripheral blood. Porcine lymphotrophic herpesvirus viral load was 
determined by quantitative PCR. Animals developing PTLD had significantly lower levels 
of T cells on the day of transplant. Cyclosporine levels did not differ significantly between 
animals with and without PTLD. Animals receiving transplants across a two-haplotype 
mismatch barrier showed an increased incidence of PTLD. All animals with PTLD had 
significant increases in PLHV-1 viral loads. Porcine lymphotrophic herpesvirus viral copy 
numbers remained at low levels in the absence of disease. The availability of a preclinical 
large-animal model with similarities to PTLD of humans may allow studies of the 
pathogenesis and treatment of that disorder. 
Spleen transplantation (SpTx) was also performed in miniature swine across full major 
histocompatibility complex barriers to study the tolerogenic effect of the spleen (Dor et al., 
2004). This study described the development of PTLD after allogeneic SpTx. Recipient pigs 
underwent whole body irradiation (100 cGy), thymic irradiation (700 cGy), and native 
splenectomy (day 0), and received a 45-day course of intravenous cyclosporine (trough level 
400-800 ng/ml). After SpTx, two of seven pigs developed PTLD (1 donor-type, 1 host-type). 
These two pigs had greater T cell depletion and higher trough levels of cyclosporine. Early 
changes that occurred prior to the development of clinical features of PTLD were increased 
porcine lymphotropic herpesvirus-1 viral loads in blood and tissues, and increased numbers 
of leukocytes, B cells, and total serum IgM. PTLD can occur after allogeneic SpTx in swine. 
This model may be useful in studies of the pathogenesis of PTLD. 
In another study using miniature swine (Doucette et al., 2007) the Porcine lymphotropic 
herpesvirus-1 (PLHV-1), a gamma-herpesvirus related to Epstein-Barr virus (EBV) was 
associated with development of PTLD following allogeneic stem cell or spleen 
transplantation. Oligonucleotide microarrays were designed based on known open reading 
frames (ORFs) of PLHV-1. Expression was compared by cohybridization of cDNA from 
lymph nodes of PLHV-1+ swine after allogeneic spleen transplantation between either: 1) 
PTLD-affected and PTLD-unaffected swine; or 2) PTLD-affected swine vs. samples from the 
same animal prior to diagnosis. In PTLD-affected animals, consistent upregulation (nine 
ORFs) and downregulation (four ORFs) of PLHV-1 mRNA was observed in comparison to 
those without PTLD. No differences in gene expression were discovered at the time of 
clinical PTLD diagnosis compared to six to nine days prior to diagnosis in the same animals. 
This model provides insights into the pathogenesis of PTLD and, by extension, potential 
diagnostic and therapeutic tools for human EBV-associated PTLD. 
4. Waldenström’s macroglobulinemia 
This disease was first identified by J. Waldenström when he reported two patients with a 
syndrome of oronasal bleeding, lymphadenopathy, an elevated sedimentation rate, 
hyperviscosity, normal bone films, cytopenias and a bone marrow with a predominantly 
lymphoid infiltrate (Waldenström, 1944). 
In the Revised European-American Lymphoma (REAL) classification, Waldenström 
macroglobulinemia (WM) has become viewed as a distinct clinicopathological entity, and is 
defined largely as a lymphoplasmacytic lymphoma (LPL); (Harris et al, 1994). The Second 
International Workshop on Waldenström macroglobulinemia attempted to refine further the 
working definition of the disease within the context of a LPL (Owen et al., 2003). For review, 
see Ansell et al., 2010. 
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Despite these efforts, the debate remains within the hematological and hematopathological 
communities with respect to nosology. These issues of definition have and continue to affect 
the interpretation of results within and across clinical trials as well as in basic and 
epidemiological research (Fonseca & Hayman, 2007). The same researchers (Fonseca & 
Hayman, 2007) used the definition of WM as proposed at the Second International 
Workshop on WM, with the exception that the original criterion of the presence of any 
degree of marrow involvement with a lymphoplasmacytoid infiltrate has been modified to 
allow a distinction to be made between an immunoglobulin (Ig) M monoclonal 
gammopathy of undetermined significance (MGUS) and WM. This change is based on 
analyses that have established the prognostic relevance and statistically significant survival 
differences among IgM MGUS (<10% marrow lymphoplasmacytic infiltrate) and 
symptomatic/smouldering WM and symptomatic/active WM(≥10% lymphoplasmacytic 
marrow infiltrate; usually intertrabecular). 
Thus, Waldenström macroglobulinemia is a B-cell lymphoproliferative disorder 
characterized by a lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue 
and a monoclonal immunoglobulin M protein (IgM) in the serum (Dimopoulos et al., 2005; 
Owen et al., 2003). Is a rare hematological neoplasm with an overall incidence of 
approximately 5 cases per 1 million persons per year, accounting for 1–2% of haematological 
malignancies (Groves et al., 1998; Herrinton & Weiss, 1993).  
The median age at diagnosis varies between 63 and 68 years, and most patients (55%-70%) 
with newly diagnosed disease are men (Dimopoulos et al., 2000). The incidence of 
Waldenström macroglobulinemia is highest among white people and is rare in other 
population groups (Benjamin et al., 2003). More specifically, WM is rare in Blacks, who 
represent only 5% of cases, and it is also rare in those of Mexican-Mestizo descent (Groves et 
al, 1998; Herrinton & Weiss, 1993; Ruiz-Arguelles et al, 2000). To date, there is no compelling 
evidence to link WM to specific occupational or environmental exposures, tobacco or 
alcohol use (Linet et al., 1993). 
The aetiology of WM remains unknown. It appears to be primarily a sporadic disease, 
although there are multiple reports of familial clustering (Blattner et al., 1980; Brown et al., 
1967; Elves & Brown, 1968; Getaz & Staples, 1977; McMaster et al., 2005; Ogmundsdottir et 
al., 1999; Renier et al., 1989; Treon et al., 2006). McMaster et al. (2006) performed a 
genomewide linkage analysis in 11 high-risk families with WM that were informative for 
linkage (including a total of 122 individuals with DNA samples). The strongest evidence of 
linkage was found on chromosomes 1q and 4q (McMaster et al., 2006). Treon et al. (2006) 
evaluated 257 patients with previously untreated WM and found that 18,7% had at least one 
first-degree relative with either WM or another B-cell disorder. In addition, those with a 
familial history had higher percentages of bone marrow involvement, were diagnosed at a 
younger age, and were more likely to have higher IgM levels upon initial presentation 
(Treon et al., 2006). 
The greatest risk factor for the development of WM is that of having an IgM MGUS. These 
patients have 46 times greater risk of developing WM than the general population (Kyle et 
al., 2002). Factors affecting the progression from IgM MGUS to WM are unknown. 
Infiltration of the bone marrow and extramedullary sites by malignant B cells and elevated 
IgM levels account for the symptoms associated with this disease. Patients may develop 
constitutional symptoms, pancytopenia, organomegaly, neuropathy, and symptoms 
www.intechopen.com
 Hematology – Science and Practice 
 
442 
associated with immunoglobulin deposition or hyperviscosity (Dimopoulos et al., 2000; 
Vijay & Gertz, 2007). However, symptoms vary considerably in individual patients. 
Although some patients present with the aforementioned symptoms, many are 
asymptomatic at the time of diagnosis. 
Waldenström macroglobulinemia is incurable with current therapy, and half of the patients 
die of disease progression; median survival is approximately 5 years (Dimopoulos et al., 1999). 
This disease is diagnosed in many patients at an advanced age, and thus approximately half of 
the patients die of causes unrelated to Waldenström macroglobulinemia. Because the disease is 
incurable and the clinical presentations, comorbidities, and causes of death vary substantially, 
the decision to treat patients and the choice of treatment can be complex. A number of 
consensus meetings have listed reasonable treatment options (Gertz et al., 2003; Treon et al., 
2006; Dimopoulos et al., 2009) but the physician is still faced with a difficult treatment decision 
in a patient with an uncommon disease. 
5. Animal models of Waldenström’s macroglobulinemia 
In 2003, the Wayne State University Waldenstrom's Macroglobulinemia xenograft model in 
mice with severe combined immune deficiency (WSU-WM-SCID) was developed (Al-Katib 
et al., 2003). The WSU-WM-SCID is a model of a more aggressive and resistant WM usually 
seen toward the late stages of disease. It is, therefore, a particularly useful tool in developing 
new therapeutic strategies for the more aggressive WM, including targeted therapy, which 
exploits unique molecular characteristics of tumor cells. The WSU-WM-SCID is the first 
preclinical animal model available for this disease. It is based on a permanent, EBV- 
IgMlambda cell line (WSU-WM) established from a patient with a 10-year history of 
Waldenstrom's macroglobulinemia. These cells are CD5(-)CD10(+)CD19(+)CD20(+)CD22(+) 
and have t(8;14) (q24;32), t(12;17) (q24;q21), 2p-. WSU-WM cells also express DNA 
topoisomerase II (alpha and beta), and are bcl(2)(+)bcl(XL)(+)bax(-). Although the tumor has 
aggressive biological behavior with c-myc-IgH rearrangement, it has retained the salient 
features of WM. The breakpoint on 8q24 is downstream of c-myc exon 3, which is not usual 
for Burkitt-type breakpoints. WSU-WM cells also express both secretory (s(u)) and 
membrane (m(u)) IgM mRNA and secrete IgM in culture supernatant. Histiologically, WSU-
WM-SCID xenograft tumors have lymphoplasmacytoid morphology. These features 
indicate biological, but not histological evolution.  
In 2005, Tassone et al., developed a novel in vivo model of human WM in severe combined 
immunodeficient (SCID) mice implanted with human fetal bone chips (SCID-hu mice) into 
which WM cells from patient bone marrow are engrafted directly into the human bone 
marrow (huBM) microenvironment. WM cells in SCID-hu mice produced human 
monoclonal paraprotein (immunoglobulin M [IgM] and/or kappa or lambda chain) 
detectable in mice sera. Immunohistochemical analysis of human bone retrieved from SCID-
hu mice showed infiltration with CD20+, IgM+, and monotypic light chain+ 
lymphoplasmacytic cells. Mast cells were observed to be associated with the infiltrate in 
these sections. Treatment of SCID-hu mice bearing WM with rituximab induced tumor 
regression, associated with a decrease in serum paraprotein. This model, therefore, 
recapitulates the in vivo biology of WM and allows the study of novel investigational drugs 
targeting WM cells in the huBM milieu. 
Model cell lines are essential tools for investigating the biology and therapeutics of cancer. 
Approximately 1500 human hematopoietic neoplastic cell lines have been described, 
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covering most major disease entities. Waldenström's macroglobulinemia (WM) is a rare 
incurable hematological neoplasm from which four cell lines have been derived. 
In 2007 a cell line, the BCWM.1 cell line (Ditzel Santos et al., 2007), which was derived from 
the long-term culture of CD19(+) selected bone marrow lymphoplasmacytic cells isolated 
from an untreated patient with WM. BCWM.1 cells morphologically resemble 
lymphoplasmacytic cells (LPC) and propagate in RPMI-1640 medium supplemented with 
10% fetal bovine serum. Phenotypic characterization by flow cytometric analysis 
demonstrated typical WM LPC characteristics: CD5(-), CD10(-), CD19(+), CD20(+), CD23(+), 
CD27(-), CD38(+), CD138(+), CD40(+), CD52(+), CD70(+), CD117(+), cIgM(+), cIgG(-),  
cIgA(-), ckappa(-), clambda(+), as well as the survival proteins APRIL and BLYS, and their 
receptors TACI, BCMA and BAFF-R. Enzyme-linked immunosorbent assay studies 
demonstrated secretion of IgMlambda and soluble CD27. Karyotypic and multicolor 
fluorescence in situ hybridization studies did not demonstrate cytogenetic abnormalities. 
Molecular analysis of BCWM.1 cells confirmed clonality by determination of IgH 
rearrangements. Inoculation of BCWM.1 cells in human bone marrow chips implanted in 
severe combined immunodeficient-hu mice led to rapid engraftment of tumor cells and 
serum detection of human IgM, lambda, and soluble CD27. These studies support the use of 
BCWM.1 cells as an appropriate model for the study of WM, which in conjunction with the 
severe combined immunodeficient-hu mouse model may be used as a convenient model for 
studies focused on both WM pathogenesis and development of targeted therapies for WM.  
In 2008, Drexler et al., summarized on the existence of three cell lines, that although are 
currently used as in vitro models, none convincingly pass muster. Mindful that candidate 
tumor cell lines sometimes arise spuriously by viral immortalization of bystander cells, they 
reviewed the extent to which WM cell lines portray established disease features in vitro. At 
closer inspection, it seems that none convincingly displays morphological, 
immunophenotypic, genotypic or biological features characteristic of WM. Rather it appears 
that two cell lines (WM1 and BCWM.1) are most probably Epstein-Barr virus-immortalized 
B-lymphoblastoid cell lines, derived from bystander B-cells. The third cell line (WSU-WM) 
carries the most common cytogenetic hallmark of Burkitt lymphoma, namely 
t(8;14)(q24;q32), while none have been shown to carry chromosome 6 deletions recently 
demonstrated as indicative of disease progression in this entity.  
Recently, Hodge et al. (2011) described the establishment of a new WM cell line, MWCL-1. 
Comprehensive genetic analyses have unequivocally confirmed a clonal relationship 
between this novel cell line and the founding tumor. MWCL-1 cells exhibit an 
immunophenotype consistent with a diverse, tumor clone composed of both small B 
lymphocytes and larger lymphoplasmacytic cells and plasma cells: CD3ま, CD19ぽ, CD20ぽ, 
CD27ぽ, CD38ぽ, CD49Dぽ, CD138ぽ, cIgMぽ, and ǋぽ. Cytogenetic studies identified a monoallelic 
deletion of 17p13 (TP53) in both the cell line and the primary tumor. Direct DNA 
resequencing of the remaining copy of TP53 revealed a missense mutation at exon 5 (V143A, 
GTG>GCG). In accordance with primary WM tumors, MWCL-1 cells retain the ability to 
secrete high amounts of IgM protein in the absence of an external stimulus. The genetic, 
immunophenotypic, and biologic data presented here confirm the validity of the MWCL-1 
cell line as a representative model of WM. 
Dr. Janz at Department of Pathology at University of Iowa is currently developing a mouse 
model of Waldenström's macroglobulinemia. An immunocompetent, transgenic mouse 
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model of human WM that will be useful for preclinical testing of WM drug candidates. 
Transgenic mouse models of human cancer are experimental model systems that rely on 
laboratory mice that have been genetically manipulated to render them prone to neoplasms 
that accurately recapitulate important features of their human cancer counterparts. Model 
systems of this sort: enable researchers to study the onset and progression of cancer in ways 
that cannot be pursued in human beings; advance our understanding of the molecular genetic 
and biological events that contribute to the development and spread of cancer cells; and 
provide a valuable preclinical platform for evaluating new approaches to treat and prevent 
cancer in patients. The latter is particularly important in circumstances in which drug testing 
requires an intact, immunocompetent animal that is able to produce the same kind of tumor 
microenvironment and recruit the same types of tumor bystander cells commonly found in 
human patients. To give but one example, therapeutic antibodies target cancer cells by 
recruiting normal immune cells to the site of attack; thus, the preclinical testing of these 
antibodies requires strains of laboratory mice that have a normal, fully functioning immune 
system. To that end, Janz and collaborators are generating a designer model of human WM 
designated C.IL6/BCL2/AIDnull. This model combines three crucial pathogenetic factors of 
human WM – namely the B-lymphocyte growth, differentiation and survival factor IL-6, the 
cellular oncoprotein BCL-2, and the inability of WM cells to perform immunoglobulin isotype 
switching (AIDnull) – on the genetic backgroud of BALB/c (abbreviated as C). Strain C mice are 
highly susceptible to malignant B-lymphocyte transformation (Diagram 1; 
http://www.medicine.uiowa.edu Pathology/site/research/ janz/res_projects.html; selected 
publications of Dr.Janz: de Jong & Janz, 2010; Park et al., 2005). 
 
Diagram 1. Schematic overview of the pathogenesis of lymphoplasmacytic lymphoma 
(LPL)-WM (panel A) and transgenic mouse strains that Janz et al. propose to use for 
modeling human LPL-WM in mice (panel B). 
(A) IL6 and BCL2 have been identified as "WM genes" – genes that confer genetic proclivity to 
the disease (left). Additionally, IL-6 and BCL-2 are major player in the LPL-WM cells (right) 
(B) All strains are on the same genetic background of BALB/c (C), an important 
precondition for intercrossing the various transgenes without jeopardizing crucial practical 
issues of this project, such as the ability to adoptively transfer fully transformed tumor cells 
or premalignant B-lineage cells from transgenic mice. We hypothesize that strain 
C.IL6/BCL2/AID-/- mice will develop IgM+ WM-like tumors. 
5.1 Waldenström’s macroglobulinemia in NOD/SCID mice 
Although important advances have been made in the classification of lymphomas, the 
remaining discrepancies in WM definition reflect the fact that the pathogenesis of this 
disease remains largely unknown.  
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As stated in the previous paragraph, the establishment of reliable animal models will 
significantly enhance research in dissecting the complicate pathogenesis of WM. In addition, 
suitable animal models may be used to assess the efficacy of existing treatments and 
develop novel therapeutic strategies (Al-Katib et al., 1993; 2003). Severe combined 
immunodeficient (SCID) mice injected with subcutaneous xenografts of neoplastic cells were 
originally used to study WM. However, the usefulness of these models is limited because 
they do not recapitulate typical features of WM, such as bone marrow localization. Recently 
developed SCID mouse WM models overcome this drawback, by utilizing subcutaneous 
implants of human fetal bone chips. The subsequent injection of bone marrow (BM) 
aspirates from WM patients directly into the fetal bone implants resulted in successful WM 
cell engraftment in 69% of animals (Tassone et al., 2005). Although this model offers a 
potential advantage in that human bone is used, fetal bone, which is at a state of rapid 
growth, clearly differs from adult bone. It is apparent that there are differences between the 
bone marrow of a newborn and an adult bone marrow, including apoptotic cells, T cells, B 
cells and macrophages, developing the microenvironment where the WM cells are being 
hosted. Not to mention the fact that human bone is made of cells forming temporary 
anatomical structures, called basic multicellular units that execute bone remodeling, which 
change with ageing of humans (Seeman, 2008). 
Our study was undertaken with the aim to develop a novel non-obese SCID (NOD-SCID) 
mouse model of WM. For that, pairs of bone particles derived from adult humans were 
successfully implanted intramuscularly in mice. Each mouse was implanted with a bone 
fragment taken from a neoplastic disease-free individual in the one hind limb and with a 
different biopsy taken from a WM patient, in the other. IgM producing neoplastic cells not 
only retained viability in the bone marrow of the WM bone biopsy but also metastasized to 
the normal bone marrow of the distant bone implant. The mouse model reported here 
improves on existing models of WM by recapitulating the adult human bone marrow 
microenvironment of abnormal WM neoplastic cells. 
For this reason, twenty-nine NOD-SCID mice (Charles River Laboratories, France) were 
used. The animals were housed in static microisolator cages at the bio-containment animal 
Research Facility of the G. Papanicolaou General Hospital. All experimental procedures and 
protocols were in accordance with the European Council Directive 86/609 as well as the 
national and institutional guidelines for animal care.  
Cancellous bone core fragments ranging from 16 to 22 mm3 in size were obtained from the 
femoral head of neoplastic disease-free adult humans during hip arthroplasty or 
hemiarthroplasty. Bone fragments were subsequently implanted into the right or left 
hindlimb muscles of 6 to 8 weeks-old mice (n=23), weighing 25 - 30 grams, as previously 
described (Tsingotjidou et al., 2001). To test viability of implanted tissue, implants were 
retrieved from 9 mice that were sacrificed at 4 (n=3), 8 (n=3) and 12 (n=3) weeks post-
implantation. Based on previous studies (Boynton et al., 1996) in order to detect 
hematopoietic cells of human origin mouse anti-human CD45 antibody (1:500; Dako, 
Carpinteria, CA) was used. Eight to twelve weeks following first bone implantation, the 
non-implanted hindlimb of the remaining 12 mice was also engrafted with a human bone 
biopsy taken from WM patients (see flow chart; Diagram 2). For that, bone marrow core 
needle biopsies (bone biopsies) were obtained from the posterior iliac crest of five patients 
with active WM during scheduled clinical visits. The biopsy was maintained in RPMI 
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medium until its use. Typically, two implants were produced from each bone biopsy. In one 
case, however, a single WM bone biopsy was large enough to be the source of 6 implants. 
All human bone biopsy donors signed Institutional Review Board-approved informed 
consent forms. Control mice received no implant (n=3) or were implanted only, either with 
non-WM (n=2) or with WM (n=3) human bone fragments (Diagram 2).  
To detect human IgM in the serum of mice, thus providing evidence for presence of human 
IgM-secreting B-cells or WM cells, mouse blood was collected from the orbital sinus of each 
mouse monthly during the experiment. Blood serum was serially tested for circulating IgM 
by ELISA (Diagnostic automation Inc., Calabasas, CA, USA).  
Mice were sacrificed at different time points ranging from 1 to 5 months following the 
implantation of WM bone biopsies (Diagram 2). At necropsy, tissues including femur, tibia, 
brain, liver, spleen, lungs, kidneys and the WM and non-WM bone grafts were collected and 
fixed in formalin. Decalcified bones together with other formalin-fixed tissues were 
processed routinely, embedded in paraffin, sectioned at 5 Ǎm, and stained with 
haematoxylin and eosin (HE) or immunohistochemistry (IHC). The latter was performed 
with mouse monoclonal antibodies directed against human CD20 (Biogenex, San Ramon, 
CA, USA), IgM (Cell Marque, Rocklin, CA, USA), and ǋ and ǌlight chains (Novocastra 
Laboratories, Newcastle-upon-Tyne, UK). Antigens were retrieved with microwave heating 
in citrate buffer (pH 6) for CD20, or with proteinase K (DAKO, Carpinteria, CA, USA) 
digestion for 6 minutes at room temperature for IgM and ǋ or ǌ chains. Poly-HRP goat anti- 
mouse IgG (Chemikon, Temecula, CA, USA) was used as secondary antibody. Signal was 
detected with diaminobenzidine and tissues were counterstained with haematoxylin. Wild 
type mouse colon along with mesenteric lymph nodes sections were used as negative tissue 
controls, whereas positive controls were procured from bone biopsy of WM patients not 
involved in the study. Irrelevant mouse antibodies were used instead of primary antibodies 
for negative staining controls. 
We (Tsingotjidou et al., 2001) and others (Yonou et al., 2001) have previously shown that 
adult human bone retains viability after engraftment subcutaneously or within the skeletal 
muscles of immunocompromised mice. In the present study, we first sought to determine 
whether the above-mentioned model of bone engraftment was successfully reproduced. For 
that, adult human cancellous bone intramuscular implants were recovered from control 
SCID mice at 4, 8 or 12 weeks post-implantation for histological evaluation. At four weeks, 
specimens showed multifocal necrosis and fibrosis. The surface of the human bone was 
lined by small numbers of osteoblast-like cells and minute amount of newly synthesized 
osteoid. In contrast, all human bone implants from intramuscularly implanted mice were 
largely normal at the 8-week time-point. Viable osteocytes and increased numbers of 
osteoblasts forming adequate amounts of osteoid were evident. However, rare foci of 
remaining osteonecrotic and fibrotic changes were noticed. At 12 weeks after implantation, 
the histology of intramuscularly implanted bone was completely restored. The population 
and spatial distribution of osteoblasts, the amounts of newly formed bone matrix, the 
restored numbers of viable osteocytes (Fig. 2A) and the presence of active bone marrow 
cavities (Fig. 2B) were all consistent with normal bone histology. The human origin of 
haematopoietic cells populating the bone marrow of implants was confirmed by IHC using 
an antibody against human CD45 that shows no cross-reactivity with mouse CD45 protein 
(Tsingotjidou et al., 2001; Boynton et al., 1996). No human lymphoid cell was found in 
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murine tissues examined. These results suggest that human bone implant was maintained 
and thrived in the mouse skeletal muscle environment. 
 
Fig. 2. Non-WM human bone implanted in the hind limb muscles of a NOD-SCID mouse at 
12 weeks post-implantation. Higher magnification of the boxed area in A is shown in B. 
Histology of the human bone is restored. Note new bone formation with viable osteoblasts 
and bone marrow reconstitution. Haematoxylin & Eosin. Bars, A: 100 Ǎm; B: 25 Ǎm. 
Three animals bearing WM bone biopsy alone were sacrificed at 1 (n=1), 2 (n=1) and 3 (n=1) 
months post implantation (Diagram 2). In all three animals, the bone marrow was diffusely 
infiltrated by neoplastic cells that had lymphocytic, plasma cell or lymphoplasmacytic 
phenotype. Tumor cells were often arranged in discrete nodules. Reactive hyperplasia of 
tumor-associated mast cells was common. Necrotic areas were evident at 1 month post 
implantation, feature that was diminished afterwards (at 2 and 3 months post implantation).  
 
Diagram 2. Flow chart of the experimental design; Time at parentheses indicates the 
sacrifice point, mos=months 
Immunohistochemically, neoplastic cells were CD20 positive. IgM-positive neoplastic cells 
were also identified in large numbers. Both CD20 and IgM antibodies used for this purpose 
was against human lymphocytes and IgM. These mice also had elevated IgM in serum at 
one month following the intramuscular implantation of the biopsy. However, two months 
post-implantation, blood IgM was moderately-to-markedly reduced. In a single mouse IgM 
fell to non-detectable levels, while in the remaining moderately elevated IgM was detectable 
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up to three months following the WM bone biopsy implantation, without reaching, 
however, the high IgM levels encountered at one month post-implantation (Tsingotjidou et 
al., 2009). Control animals that received no implant (n=3) or were implanted only with non-
WM (n=2) showed no elevation in serum IgM throughout the duration of experiment. Upon 
histological and IHC examination control mice had no detectable lymphocytes or plasma 
cells in all tissues examined. 
Twelve animals (n=12) implanted with both WM and non-WM bones were monitored for 
serum IgM levels throughout the experiment. Necropsies were performed in nine of those 
(9/12) at 3 (n=5), 4 (n=3) and 5 (n=1) months following implantation of WM bone biopsies 
(Diagram 2). Histopathological and immunohistochemical analysis of WM implants in these 
mice (n=9) yielded similar results as those described in the control mice bearing WM bone 
biopsy alone (n=3), namely a CD20+, IgM+ neoplastic cell infiltrate. These results indicated 
that survival of neoplastic cells in this experimental model could be prolonged for at least 5 
months post implantation. Interestingly, histopathology and IHC analysis of the 
controlateral, non-WM implant of 4 out 9 mice revealed that the bone marrow was 
infiltrated by large numbers of neoplastic cells (Fig. 3). In order to confirm the validity of 
our findings, clonality by staining against ǋ- and ǌ- light chains was documented in two, 
randomly selected animals (W6 and W10). Cytoplasmic immunolabelling for ǋ- but not for 
ǌ-light chains was evident and restricted specifically and exclusively within the plasmacytic 
component of the tumor (Fig. 4). Thus, light chain predominance confirmed the clonality of 
neoplastic cells. Sparsely dispersed IgM positive cells were found in the bone marrow of 
tibia and femur of one animal (W10). Diffuse infiltration of WM cells was also seen in the 
liver and kidney of another animal (W44).  
 
Fig. 3. CD20-specific (A and B) and IgM-specific (C and D) immunohistochemistry of human 
bone implants. Large numbers of human CD20-positive (A) and IgM-positive (C) WM cells 
remain viable in the bone marrow of the WM bone biopsy implanted in NOD-SCID mice. 
CD20-positive (B) and IgM-positive (D) cells could also be detected at the non-WM human 
bone that was distantly implanted in the same mice. Haematoxylin counterstain, DAB 
chromogen. Bars: 25 Ǎm.  
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Fig. 4. ǋ (A and B) and ǌ (C and D) chain immunophenotyping of neoplastic cells performed 
in consecutive histological sections taken from both WM (A and C) and non-WM (B and D) 
bone implants of the same mouse. ǋ-chain-positive cell predominance in both implants 
provided evidence for the clonality of neoplastic cells. Haematoxylin counterstain, DAB 
chromogen. Bars: 50 Ǎm 
Serum IgM values in all mice implanted with both WM and non-WM bone biopsies  (n=12) 
correlated with histopathological observations and IHC analysis for neoplastic cell density 
and metastatic growth. Indeed, mice with increased neoplastic cell burden and controlateral 
bone implant metastasis (W10, W44, W52 and W6) had increased IgM values in their blood 
serum (Tsingotjidou et al., 2009). In contrast, mice with sparse neoplastic cells in the WM 
implant and no evidence of metastasis (W45, W51 and W50) had low or non-detectable 
levels of serum IgM. It is interesting that 2 out of these 3 mice received implants originating 
from patients that had the two lowest percentages of bone marrow infiltration by neoplastic 
cells (20% and 33%) among human bone biopsy donors in this study. In a single mouse 
(W46), a sudden abolishment of serum IgM levels was observed at the 4th month post 
implantation of the WM bone (Tsingotjidou et al., 2009). Histological evidence of necrosis 
found in both implanted bone fragments examined, however, explained this abnormality.  
Overall analysis of the monthly records of serum IgM values of mice used in this study 
reveals that after the second month, there is an overall progressive rise of IgM during 
months 3 and 4 post implantation of the WM biopsy (Tsingotjidou et al., 2009). 
Taken together these results suggest that the WM neoplastic cells in the bone marrow of 
adult human bone implanted in SCID mice not only survive and grow but also are capable 
of producing IgM and metastasize (Tsingotjidou et al., 2009). The relatively high value of 
IgM obtained one month after implantation is considered an artifact attributable to cell 
damage, as discussed below.  
www.intechopen.com
 Hematology – Science and Practice 
 
450 
This study described a novel NOD-SCID mouse model of WM. Using the SCID mouse as a 
vehicle of two human adult bone intramuscular implants we demonstrated that IgM 
producing WM neoplastic cells retain viability in the bone marrow of the implant 
originating from WM patients. Interestingly, neoplastic cells not only grew but also 
metastasized to the normal bone marrow of the second distant bone implant (Fig. 3). 
A significant drawback in understanding pathogenesis of WM and developing novel 
therapeutics is the lack of animal models that recapitulate most features of human WM. 
Hence, several studies have focused in the development of animal models to study this rare 
but incurable neoplastic disease. In the past, attempts to grow WM cells in vitro or engraft 
them in immunocompromised mice have failed (Al-Katib et al., 2003). This probably was 
due to the lack of human bone marrow stromal cells, which are important elements of tumor 
microenvironment and facilitate both survival and proliferation of WM cells. Recently, 
however, important advances have been made utilizing SCID mice that were implanted 
with human fetal bone chips. The bone marrow of fetal bone implants successfully 
supported the survival and growth of WM cells derived either directly from patients 
(Tassone et al., 2005) or from a WM cell line that was established for that purpose (Santos et 
al., 2007). Both those experimental models are important, since they recapitulate a typical 
feature of the human disease, which is the bone marrow microenvironment-depended 
growth of WM cells. However, the natural niche of WM cells is the adult and not the fetal 
bone marrow that both these studies utilized for the engraftment of malignant cells. Adult 
and fetal bone marrow may differ in the pattern of growth stimuli imparted to WM cells. 
Although these differences cannot be elucidated, without elaborate research, the murine 
model of WM proposed in the present study overcomes this skepticism by simply using 
adult human bone implants. 
An interesting observation of this study was that mice implanted with a WM bone fragment, 
showed elevation of blood IgM one month following the implantation. This peak in IgM levels 
observed at the first month coincided with the period of maximum damage to the implanted 
bone particle (Tsingotjidou et al., 2001). This particular elevation, however, may not reflect an 
active secretion of IgM from WM cells, but rather be due to an initial phase of ischaemic injury 
leading to WM cell necrosis and subsequent IgM leak. Indeed, histological studies of the 
human bone implants performed in the present study matched our previous observations 
(Tsingotjidou et al., 2001), which indicated that 8-12 weeks are needed before implanted bones 
become adequately vascularized, and restore their pre-transplant normal histology. A similar 
phenomenon of IgM release is well characterized in human patients following effective anti-
neoplastic treatment, due to WM cell damage (Treon et al., 2004). For that reason, only IgM 
serum values obtained from the second month onwards were taken into consideration and 
were used as reliable indicators of disease burden of the implanted mice. 
The wide range of IgM levels observed in mice of our experiments mimic analogous 
findings in humans. Accumulated data suggest that the levels of IgM production are highly 
variable among WM patients. Therefore, such data are valuable for follow-up examinations 
of individual patients and do not represent a universal indicator of WM burden. 
Irrespectively of initial IgM levels, however, most mice used in this study showed a similar 
pattern of IgM fluctuation over time. Following an elevation of IgM at the first month and a 
subsequent reduction at the second month, which can be considered baseline, there was a 
progressive rise of IgM during months 3 and 4 post implantation of the WM biopsy.  
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An interesting feature of the WM murine model presented here is the observed metastasis of 
the malignant cells. In approximately half of mice implanted with both WM and non-WM 
bone implants, WM cells metastasized from the affected implant to the healthy one, which 
was located in the contralateral hindlimb. Human bone, albeit from unrelated individual, 
was colonized preferentially, since metastasis to murine bone was observed only in a single 
mouse. Accordingly, existing murine models of WM show either no (Santos et al., 2007) or 
rare (Tassone et al., 2005) metastases to murine tissues. It is possible, that WM cells 
engrafted in mice could infrequently acquire novel properties that allow them to traffic, 
home and survive in murine bone marrow or other tissues. Obviously, accumulated genetic 
abnormalities driven by a physical selection process, may result in WM cells able to survive 
in the murine microenvironment. However, these genetic alterations render these cells less 
appropriate to model metastatic phenomena occurring in human WM, which is 
predominately an indolent disease. The murine model developed in the present study 
overcomes inherited disadvantages of existing WM in vivo models and better recapitulates 
metastasis, since it is supporting relocation of primary WM cells derived from patients from 
one human bone implant to another.  
6. Conclusion  
The use of bone biopsies taken from different WM patients as implants in SCID mice 
appears as highly attractive biological system to study aspects of the human disease. The 
quantitative limitation of harvesting BM particles from patients restricts the possibility to 
produce large highly homogeneous experimental groups of mice, given the variability of 
biological behaviour of WM among patients. This fact is exemplified by the results of the 
present study. Indeed, high levels of serum IgM and infiltration of the contralateral non-
WM bone biopsy, by WM cells did not occur consistently in all mice. Hence, we reason that 
this model may not be suitable for screening specific therapeutic factors of WM. For such 
studies, the adult bone implant approach might still be considered if the healthy bone was 
artificially populated with WM cell line. On the other hand, the experimental design used in 
the present study may be useful for studying the pathogenesis of WM and particularly the 
interaction with the bone marrow stroma as it exists in the adult bone marrow. It may also 
be an ideal setting for studying the disease in long term, since the model allows indolent 
growth in mice, and consequently to assess the pathophysiology of epiphenomena such as 
neuropathy (work in progress). It is believed that the experimental setting as presented here 
will contribute to the unraveling of the etiology and pathogenesis of WM to the benefit of 
the patients.  
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